Key result
PCSK9 inhibitors are linked to slower eGFR decline in patients at high risk of CKD progression.
Why the study?
Do PCSK9 inhibitors slow eGFR decline in patients at high risk of CKD progression?
Do PCSK9 inhibitors slow eGFR decline in patients at high risk of CKD progression?
Answers are grounded in this paper and cite their sources.
PCSK9 inhibitors may slow the decline of eGFR in patients at high risk for CKD progression.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Nunzio et al. (2026) studied this question. PCSK9 inhibitors were associated with a slower decline in eGFR among patients at high risk of chronic kidney disease progression.
Synapse has enriched 10 related papers. Consider them for comparative context: